[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654630":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":20,"studyPopulation":21,"armGroups":16,"interventions":16,"overallOfficials":22,"centralContacts":26,"locations":16,"responsibleParty":35,"collaborators":16,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":16,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":16,"enrollmentInfo":49,"targetDuration":16,"studyType":52,"phases":16,"briefSummary":53,"conditions":54,"keywords":16,"overallStatus":56,"whyStopped":16,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":16},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Assessment of asprosin level in behcet disease and its association with disease activity","To investigate serum asprosin level in behcet disease","Baseline",{"measure":10,"description":14,"timeFrame":15},"To investigate serum Asprosin concentrations in patients with BD.","Baseline assessment at the time of enrollment",null,{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":18,"timePerspective":19,"maskingInfo":16},"CASE_CONTROL","CROSS_SECTIONAL","Behçet's disease (BD) is a chronic, recurrent, multisystem inflammatory vasculitis characterized by various systemic manifestations involving all vessel sizes in both the arterial and venous systems \\[1,2\\].\n\nGiven that BD is a prototypical systemic vasculitis in which endothelial damage and vascular inflammation are central pathogenic mechanisms, the identification of novel biomarkers reflecting vascular involvement is of major clinical importance\\[3\\].\n\nAsprosin is an adipokine that beyond its metabolic effects, carries growing evidence suggesting its associated with vascular pathologies \\[4\\].\n\nExperimental and clinical studies have demonstrated that Asprosin contributes to endothelial dysfunction, induces phenotypic switching in vascular smooth muscle cells, and facilitates vascular remodeling by activating pro-inflammatory signaling pathways such as TLR4-NF-κB-NLRP3 \\[4,5\\]. Furthermore, Asprosin has been implicated in endothelial-to-mesenchymal transition through TGF-β signaling, thereby exacerbating peripheral arterial disease and vascular stiffness\\[4,5\\]. Although endothelial dysfunction and surrogate markers of vascular injury (e.g., impaired flow-mediated dilation, increased intima-media thickness, oxidative stress markers) have been extensively studied in BD\\[3\\], the role of Asprosin in this disease remains unexplored.\n\nIn this context, Asprosin may represent a link between metabolic pathways and immune mediated vascular inflammation, warranting investigation in systemic vasculitis as potential biomarkers of disease activity \\[6\\].","The study will include adult patients with Behçet's disease fulfilling the International Criteria for Behçet's Disease (ICBD), as well as age- and sex-matched healthy controls. Patients will be recruited from the Rheumatology Department. The study will assess serum Asprosin levels in relation to disease activity in Behçet's disease.",[23],{"name":24,"affiliation":5,"role":25},"Marwa Ahmed Abdel- aziz Galal, MD","STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":16,"email":31},"Eman Ahmed Ibrahim","CONTACT","01155359235","eymanahmad159@gmail.com",{"name":33,"role":29,"phone":34,"phoneExt":16,"email":16},"Samar Hasanein Goma, MD","01061828586",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"PRINCIPAL_INVESTIGATOR","Eman Ahmed Ibrahim Hasan","Doctor","100654630","asprosin-in-behect-patients-100654630",false,"NCT07803198","Asprosin in Behect Patients","Asprosin as a Potential Biomarker for Disease Activity in Behcet Disease","Inclusion Criteria:\n\n* Adult subjects (≥ 18 years) satisfying the International Criteria for Behçet's Disease (ICBD) will be included in \\[7\\].\n\nExclusion Criteria:\n\n* Patients with other autoimmune diseases.\n* Patients with Acute inflammatory condition at the time of blood sampling.\n* Pregnant participants, and participants with active infection, known malignancy, diabetes mellitus, chronic kidney or liver disease, thyroid or other endocrine disorders, obesity.",true,"ALL","18 Years",{"count":50,"type":51},44,"ESTIMATED","OBSERVATIONAL","This study aims to investigate serum Asprosin concentrations in patients with BD and their relationship with disease activity and major clinical manifestations.",[55],"Behcet Disease","NOT_YET_RECRUITING","2026-08-31",{"date":59,"type":60},"2026-09-03","ACTUAL",{"date":62,"type":51},"2026-09-01",{"date":64,"type":51},"2027-10-30",{"name":5,"class":6}]